GAVISCON EXTRA STRENGTH 500 PEPPERMINT TABLETS
Active substance: SODIUM BICARBONATE
View full screen / Print PDF » Download PDF ⇩
Transcript
1.
NAME OF THE MEDICINAL PRODUCT Gaviscon Extra Strength 500 Peppermint Tablets.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains sodium alginate 500mg, sodium bicarbonate 267mg and calcium carbonate 160mg. For excipients, see Section 6.1.
3.
PHARMACEUTICAL FORM Chewable tablet. An off-white to cream, circular, flat with bevelled edges tablet with the odour and flavour of peppermint.
4.
4.1.
CLINICAL PARTICULARS
Therapeutic indications Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and acid indigestion, for example, following meals or during pregnancy.
4.2.
Posology and method of administration For oral administration, after being thoroughly chewed. Adults and children 12 years and over: One to two tablets after meals and at bedtime. Children under 12 years: Should be given only on medical advice. Elderly: No dose modifications necessary for this age group.
4.3.
Contraindications None.
4.4.
Special warnings and precautions for use
The sodium content of two-tablet dose is 246 mg (10.6 mmol). This should be taken into account when highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment. Each two-tablet dose contains 320 mg (3.2 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi. Due to its aspartame content this product should not be given to patients with phenylketonuria. There is a possibility of reduced efficacy in patients with very low levels of gastric acid. If symptoms do not improve after seven days, the clinical situation should be reviewed. Treatment of children younger than 12 years of age is not generally recommended, except on medical advice.
4.5.
Interactions with other medicinal products and other forms of interaction None known.
4.6.
Pregnancy and lactation Open controlled studies in 281 pregnant women did not demonstrate any significant adverse effects of Gaviscon on the course of pregnancy or on the health of the foetus/new-born child. Based on this and previous experience Gaviscon Extra Strength 500 Peppermint Tablets may be used during pregnancy and lactation.
4.7.
Effects on ability to drive and use machines None.
4.8
Undesirable effects Very rarely (<1/10,000) patients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions.
4.9.
Overdose In the event of overdosage symptomatic treatment should be given. The patient may notice abdominal distension.
5.
5.1.
PHARMACOLOGICAL PROPERTIES
Pharmacodynamic properties Pharmacotherapeutic classification: A02BX 13. Other drugs for peptic ulcer and gastrooesophageal reflux disease. On ingestion Gaviscon Extra Strength 500 Peppermint Tablets react rapidly with gastric acid to form a raft of alginic acid gel having a near neutral pH and which floats on the stomach contents effectively impeding gastro-oesophageal reflux. In severe cases the raft itself may be refluxed into the oesophagus, in preference to the stomach contents, and exert a demulcent effect.
5.2.
Pharmacokinetic properties The mode of action of Gaviscon Extra Strength 500 Peppermint Tablets is physical and does not depend on absorption into the systemic circulation.
5.3.
Preclinical safety data No preclinical findings of relevance to the prescriber have been reported.
6.
6.1.
PHARMACEUTICAL PARTICULARS
List of excipients Lemon flavour no. 1 Marcrogol 20,000 Mannitol (E421) Copovidone Aspartame (E951) Acesulfame potassium (E950) Magnesium stearate
6.2.
Incompatibilities Not applicable.
6.3.
Shelf life Two years.
6.4.
Special precautions for storage Do not store above 30C. Store in the original package.
6.5.
Nature and contents of container
Unprinted, glass-clear, thermoformable laminate of uPVC/PE/PVdC with aluminium foil lidding blister trays into cartons. Blister tray containing six or ight individually sealed tablets. Two, four, six or eight blister trays in a carton. Not all pack sizes may be marketed
6.6.
Instruction for use and handling (, and disposal)
No special instructions.
No Data Held 7. MARKETING AUTHORISATION HOLDER Reckitt Benckiser Healthcare (UK) Limited Dansom Lane Hull HU8 7DS United Kingdom.
8.
MARKETING AUTHORISATION NUMBER PL 00063/0138
9.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 7 October 2003
10
DATE OF REVISION OF THE TEXT
27/01/2011
NAME OF THE MEDICINAL PRODUCT Gaviscon Extra Strength 500 Peppermint Tablets.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains sodium alginate 500mg, sodium bicarbonate 267mg and calcium carbonate 160mg. For excipients, see Section 6.1.
3.
PHARMACEUTICAL FORM Chewable tablet. An off-white to cream, circular, flat with bevelled edges tablet with the odour and flavour of peppermint.
4.
4.1.
CLINICAL PARTICULARS
Therapeutic indications Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and acid indigestion, for example, following meals or during pregnancy.
4.2.
Posology and method of administration For oral administration, after being thoroughly chewed. Adults and children 12 years and over: One to two tablets after meals and at bedtime. Children under 12 years: Should be given only on medical advice. Elderly: No dose modifications necessary for this age group.
4.3.
Contraindications None.
4.4.
Special warnings and precautions for use
The sodium content of two-tablet dose is 246 mg (10.6 mmol). This should be taken into account when highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment. Each two-tablet dose contains 320 mg (3.2 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi. Due to its aspartame content this product should not be given to patients with phenylketonuria. There is a possibility of reduced efficacy in patients with very low levels of gastric acid. If symptoms do not improve after seven days, the clinical situation should be reviewed. Treatment of children younger than 12 years of age is not generally recommended, except on medical advice.
4.5.
Interactions with other medicinal products and other forms of interaction None known.
4.6.
Pregnancy and lactation Open controlled studies in 281 pregnant women did not demonstrate any significant adverse effects of Gaviscon on the course of pregnancy or on the health of the foetus/new-born child. Based on this and previous experience Gaviscon Extra Strength 500 Peppermint Tablets may be used during pregnancy and lactation.
4.7.
Effects on ability to drive and use machines None.
4.8
Undesirable effects Very rarely (<1/10,000) patients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions.
4.9.
Overdose In the event of overdosage symptomatic treatment should be given. The patient may notice abdominal distension.
5.
5.1.
PHARMACOLOGICAL PROPERTIES
Pharmacodynamic properties Pharmacotherapeutic classification: A02BX 13. Other drugs for peptic ulcer and gastrooesophageal reflux disease. On ingestion Gaviscon Extra Strength 500 Peppermint Tablets react rapidly with gastric acid to form a raft of alginic acid gel having a near neutral pH and which floats on the stomach contents effectively impeding gastro-oesophageal reflux. In severe cases the raft itself may be refluxed into the oesophagus, in preference to the stomach contents, and exert a demulcent effect.
5.2.
Pharmacokinetic properties The mode of action of Gaviscon Extra Strength 500 Peppermint Tablets is physical and does not depend on absorption into the systemic circulation.
5.3.
Preclinical safety data No preclinical findings of relevance to the prescriber have been reported.
6.
6.1.
PHARMACEUTICAL PARTICULARS
List of excipients Lemon flavour no. 1 Marcrogol 20,000 Mannitol (E421) Copovidone Aspartame (E951) Acesulfame potassium (E950) Magnesium stearate
6.2.
Incompatibilities Not applicable.
6.3.
Shelf life Two years.
6.4.
Special precautions for storage Do not store above 30C. Store in the original package.
6.5.
Nature and contents of container
Unprinted, glass-clear, thermoformable laminate of uPVC/PE/PVdC with aluminium foil lidding blister trays into cartons. Blister tray containing six or ight individually sealed tablets. Two, four, six or eight blister trays in a carton. Not all pack sizes may be marketed
6.6.
Instruction for use and handling (, and disposal)
No special instructions.
No Data Held 7. MARKETING AUTHORISATION HOLDER Reckitt Benckiser Healthcare (UK) Limited Dansom Lane Hull HU8 7DS United Kingdom.
8.
MARKETING AUTHORISATION NUMBER PL 00063/0138
9.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 7 October 2003
10
DATE OF REVISION OF THE TEXT
27/01/2011
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
